What is Vitalograph?
Established in 1963, Vitalograph has evolved into a global leader in respiratory diagnostic products and clinical drug trial services. The company provides a comprehensive suite of solutions designed to empower healthcare professionals with accurate, reliable data, facilitating superior patient outcomes across more than 110 countries. With a significant operational footprint in the United States since 1969, the organization bridges the gap between complex pulmonary research and practical clinical application. Its market position is defined by a commitment to high-fidelity diagnostic instrumentation, which remains essential for both routine clinical practice and the rigorous requirements of international pharmaceutical trials.
How much funding has Vitalograph raised?
Vitalograph has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Vitalograph
PPP
Public-Private Partnership
What's next for Vitalograph?
With the successful completion of this late-stage funding round, Vitalograph is well-positioned to accelerate its strategic initiatives in the digital health and remote monitoring sectors. The capital will likely be deployed to enhance the scalability of its clinical trial service offerings and to integrate advanced data analytics into its existing diagnostic hardware portfolio. As the global healthcare industry shifts toward decentralized clinical trials and personalized respiratory care, Vitalograph is poised to leverage its deep domain expertise to capture additional market share. The focus remains on maintaining its reputation for technical excellence while expanding its reach into emerging markets where the demand for high-quality respiratory diagnostics is experiencing rapid growth.
See full Vitalograph company page
